ES2721174T3 - Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina - Google Patents

Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina Download PDF

Info

Publication number
ES2721174T3
ES2721174T3 ES11183613T ES11183613T ES2721174T3 ES 2721174 T3 ES2721174 T3 ES 2721174T3 ES 11183613 T ES11183613 T ES 11183613T ES 11183613 T ES11183613 T ES 11183613T ES 2721174 T3 ES2721174 T3 ES 2721174T3
Authority
ES
Spain
Prior art keywords
retina
treatment
degenerative diseases
rpe cells
human embryonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11183613T
Other languages
English (en)
Inventor
Irina Klimanskaya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Institute for Regenerative Medicine
Original Assignee
Astellas Institute for Regenerative Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Institute for Regenerative Medicine filed Critical Astellas Institute for Regenerative Medicine
Application granted granted Critical
Publication of ES2721174T3 publication Critical patent/ES2721174T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/062—Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0621—Eye cells, e.g. cornea, iris pigmented cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/33—Insulin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Abstract

Un método para diferenciar citoblastos embrionarios humanos en células de RPE humano, comprendiendo dicho método: a) permitir el sobrecrecimiento de cultivos de citoblastos embrionarios humanos en MEF; b) permitir que los cultivos de citoblastos embrionarios humanos formen una multicapa de células espesa; c) cultivar los citoblastos embrionarios humanos para formar células de RPE pigmentadas; y d) aislar y cultivar las células de RPE pigmentadas del cultivo de la etapa (c) para formar las células de RPE humano.
ES11183613T 2004-01-23 2005-01-24 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina Active ES2721174T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53896404P 2004-01-23 2004-01-23

Publications (1)

Publication Number Publication Date
ES2721174T3 true ES2721174T3 (es) 2019-07-29

Family

ID=34807248

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11183613T Active ES2721174T3 (es) 2004-01-23 2005-01-24 Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina

Country Status (15)

Country Link
US (6) US7736896B2 (es)
EP (8) EP2438815A3 (es)
JP (10) JP2007522131A (es)
KR (3) KR101258292B1 (es)
CN (3) CN104434979A (es)
AU (6) AU2005207042B2 (es)
BR (1) BRPI0507074A (es)
CA (2) CA2555370C (es)
ES (1) ES2721174T3 (es)
HK (3) HK1216068A1 (es)
IL (3) IL177015B (es)
MX (2) MX2020009456A (es)
NZ (1) NZ548929A (es)
SG (4) SG10201606441SA (es)
WO (1) WO2005070011A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043614B2 (en) 2004-03-09 2011-10-25 Ahlfors Jan-Eric W Autogenic living scaffolds and living tissue matrices: methods and uses thereof
SG10201606441SA (en) * 2004-01-23 2016-09-29 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
US7794704B2 (en) 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
US7893315B2 (en) 2004-11-04 2011-02-22 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
CN1966080B (zh) * 2005-11-17 2011-06-08 李凌松 一种治疗老年痴呆症、帕金森病的神经干细胞注射液
US7541186B2 (en) * 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
WO2007130664A2 (en) 2006-05-03 2007-11-15 Advanced Cell Technology, Inc. Derivation of embryonic stem cells and embryo-derived cells
US9133435B2 (en) * 2007-01-18 2015-09-15 Riken Method for induction/differentiation into photoreceptor cell
EP2982744A1 (en) 2007-02-23 2016-02-10 Advanced Cell Technology, Inc. Highly efficient methods for reprogramming differentiated cells and for generating animals and embryonic stem cells from reprogrammed cells
JP5395058B2 (ja) * 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
US8574567B2 (en) 2007-05-03 2013-11-05 The Brigham And Women's Hospital, Inc. Multipotent stem cells and uses thereof
EP2155860B1 (en) 2007-05-03 2014-08-27 The Brigham and Women's Hospital, Inc. Multipotent stem cells and uses thereof
US20090028831A1 (en) * 2007-07-23 2009-01-29 University Of Kentucky Research Foundation Stem cell regulator, compositions and methods of use
AU2015201435B2 (en) * 2007-10-12 2017-02-02 Astellas Institute For Regenerative Medicine Improved methods of producing RPE cells and compositions of RPE cells
AU2008312007A1 (en) 2007-10-12 2009-04-23 Advanced Cell Technology, Inc. Improved methods of producing RPE cells and compositions of RPE cells
US8481313B2 (en) * 2008-04-22 2013-07-09 Regenerative Research Foundation Retinal pigment epithelial stem cells
WO2011028524A1 (en) 2009-08-24 2011-03-10 Wisconsin Alumni Research Foundation Substantially pure human retinal progenitor, forebrain progenitor, and retinal pigment epithelium cell cultures and methods of making the same
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
EP3549617B1 (en) 2010-07-12 2023-09-13 University of Southern California Biocompatible substrate for facilitating interconnections between stem cells and target tissues and methods for implanting same
CA2806127C (en) 2010-07-23 2021-12-21 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2013015835A1 (en) 2011-07-22 2013-01-31 Seven Networks, Inc. Mobile application traffic optimization
JP2012231786A (ja) * 2011-04-18 2012-11-29 Kyushu Univ 標的遺伝子の発現変化による食品機能成分及び医薬品感受性評価方法
WO2012149468A2 (en) 2011-04-29 2012-11-01 University Of Southern California Instruments and methods for the implantation of cell-seeded substrates
US8877489B2 (en) 2011-12-05 2014-11-04 California Institute Of Technology Ultrathin parylene-C semipermeable membranes for biomedical applications
US9932560B2 (en) 2011-05-13 2018-04-03 Elixirgen, Llc Use of Zscan4 and Zscan4-dependent genes for direct reprogramming of somatic cells
SG10201912961QA (en) * 2011-05-18 2020-03-30 Univ California Compositions and Methods for Treating Retinal Diseases
CN103007355B (zh) * 2011-09-20 2014-08-13 同济大学 一种水凝胶-纳米纤维膜及其制备方法和用途
DK2780022T3 (da) * 2011-11-14 2019-07-15 Astellas Inst For Regenerative Medicine Farmaceutiske præparater af humane rpe-celler og anvendelser deraf
US8961956B2 (en) 2011-11-30 2015-02-24 Ocata Therapeutics, Inc. Mesenchymal stromal cells and uses related thereto
DK2785359T3 (en) 2011-11-30 2018-10-29 Astellas Inst For Regenerative Medicine MESENKYMAL STROMACELLES AND APPLICATIONS RELATED
US9248013B2 (en) 2011-12-05 2016-02-02 California Institute Of Technology 3-Dimensional parylene scaffold cage
WO2013123292A1 (en) * 2012-02-17 2013-08-22 The Schepens Eye Research Institute Phenotype profile of human retinal progenitor cells
US10519422B2 (en) 2012-02-29 2019-12-31 Riken Method of producing human retinal pigment epithelial cells
SG11201501319PA (en) * 2012-08-24 2015-04-29 Riken Method for producing retinal pigment epithelial cell sheet
US11241460B2 (en) 2013-03-15 2022-02-08 Astellas Institute For Regenerative Medicine Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
CA2906815A1 (en) * 2013-03-15 2014-09-18 Ocata Therapeutics, Inc. Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
WO2014157257A1 (ja) * 2013-03-25 2014-10-02 公益財団法人先端医療振興財団 細胞の選別方法
EP2796545A1 (en) * 2013-04-26 2014-10-29 Université Pierre et Marie Curie (Paris 6) Methods for obtaining retinal progenitors, retinal pigmented epithelial cells and neural retinal cells
US11624053B2 (en) 2013-11-27 2023-04-11 Kyoto Prefectural Public University Corporation Application of laminin to corneal endothelial cell culture
AU2014363032A1 (en) 2013-12-11 2016-06-09 Pfizer Limited Method for producing retinal pigment epithelial cells
JP6770435B2 (ja) * 2014-10-31 2020-10-14 京都府公立大学法人 ラミニンによる網膜および神経の新規治療
CN113559246A (zh) 2014-10-31 2021-10-29 京都府公立大学法人 使用层粘连蛋白的新的角膜的治疗
WO2016154357A1 (en) 2015-03-23 2016-09-29 Ocata Therapeutics, Inc. Improved assays for potency of human retinal pigment epithelium (rpe) cells and photoreceptor progenitors
EP3334415A1 (en) 2015-08-18 2018-06-20 Astellas Institute for Regenerative Medicine Clinical formulations
AU2016320991C1 (en) 2015-09-08 2023-04-06 Healios K.K. Method for producing retinal pigment epithelial cells
DK3347457T3 (da) 2015-09-08 2022-01-17 Fujifilm Cellular Dynamics Inc MACS-baseret oprensning af stamcelleafledt retinalt pigmentepitel
WO2017070337A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Methods for directed differentiation of pluripotent stem cells to immune cells
CN106609255B (zh) * 2015-10-22 2019-11-05 同济大学 含pj34和视网膜色素上皮细胞的细胞悬液及其应用
CN106609263B (zh) * 2015-10-22 2020-04-07 同济大学 高效诱导多能干细胞向视网膜色素上皮细胞分化的方法
CN106609256B (zh) * 2015-10-22 2020-04-07 同济大学 体外诱导人胚胎干细胞分化为视网膜色素上皮细胞的方法
CN106609257B (zh) * 2015-10-22 2020-04-10 同济大学 高效分离体外诱导的rpe细胞和rpc的方法
CN106282096A (zh) * 2016-10-19 2017-01-04 江苏艾尔康生物医药科技有限公司 一种人类视网膜色素上皮细胞层的分离培养方法
CN110573610A (zh) 2017-03-08 2019-12-13 大日本住友制药株式会社 视网膜色素上皮细胞的制备方法
EP3595687A1 (en) * 2017-03-16 2020-01-22 Lineage Cell Therapeutics, Inc. Methods for measuring therapeutic effects of retinal disease therapies
WO2019054515A1 (ja) * 2017-09-14 2019-03-21 国立研究開発法人理化学研究所 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法
AU2018369975B2 (en) 2017-11-15 2022-05-19 Friedrich Miescher Institute For Biomedical Research Primate retinal pigment epithelium cell-specific promoter
CN108029638B (zh) * 2017-12-04 2020-04-21 四川省人民医院 一种视网膜色素变性疾病动物模型的构建方法及应用
US11946069B2 (en) 2018-03-12 2024-04-02 RxCell, Inc. Method for generating multiple cellular products from single pluripotent cell source
AU2020260894A1 (en) 2019-04-26 2021-11-18 Riken Composite including neural retina, retinal pigment epithelial cells, and hydrogel, and method for producing same
US20230072771A1 (en) 2019-10-30 2023-03-09 Astellas Institute For Regenerative Medicine Methods for producing retinal pigment epithelium cells
RU2730937C1 (ru) * 2019-11-01 2020-08-26 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Миндрава России) Способ трансплантации клеток ретинального пигментного эпителия (РПЭ), дифференцированных из индуцированных плюрипотентных стволовых клеток человека, при атрофии ретинального пигментного эпителия
EP4306634A1 (en) 2021-03-09 2024-01-17 Riken Method for producing hypoimmunogenic retinal pigment epithelial cells
US20230377685A1 (en) 2022-04-15 2023-11-23 Aspen Neuroscience, Inc. Methods of classifying the differentiation state of cells and related compositions of differentiated cells

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3490447B2 (ja) 1993-04-30 2004-01-26 フォトジェネシス インコーポレイテッド 網膜色素上皮移植
US6878544B2 (en) 1996-04-19 2005-04-12 Neurotech Sa Retinal cell lines with extended life-span and their applications
US20040086494A1 (en) * 1996-10-07 2004-05-06 John Constance Mary Immune privileged cells for delivery of proteins and peptides
JP2001508302A (ja) 1997-01-10 2001-06-26 ライフ テクノロジーズ，インコーポレイテッド 胚性幹細胞血清置換
US6331406B1 (en) * 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
WO1999034834A1 (en) 1998-01-02 1999-07-15 Titan Pharmaceuticals, Inc. Use of pigmented retinal epithelial cells for creation of an immune privilege site
AU2884499A (en) 1998-03-02 1999-09-20 Compucyte Corp. Selective cell analysis
US6667176B1 (en) * 2000-01-11 2003-12-23 Geron Corporation cDNA libraries reflecting gene expression during growth and differentiation of human pluripotent stem cells
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
BR0015148A (pt) 1999-10-28 2002-07-16 Univ Massachusetts Produção androgenética ou ginogenética de linhas de células e células pluripotentes, e seu uso para produzir tecidos e células diferenciados
JP3454206B2 (ja) * 1999-11-10 2003-10-06 三菱電機株式会社 雑音抑圧装置及び雑音抑圧方法
EP1248517A2 (en) * 2000-01-07 2002-10-16 Oregon Health and Science University Clonal propagation of primate offspring by embryo splitting
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
US20030084471A1 (en) * 2000-03-16 2003-05-01 David Beach Methods and compositions for RNA interference
US6458589B1 (en) 2000-04-27 2002-10-01 Geron Corporation Hepatocyte lineage cells derived from pluripotent stem cells
AU2001284160A1 (en) 2000-08-19 2002-03-04 Axordia Limited Modulation of stem cell differentiation
US6576464B2 (en) 2000-11-27 2003-06-10 Geron Corporation Methods for providing differentiated stem cells
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
DE10108412B4 (de) * 2001-02-21 2006-03-09 Cevec Pharmaceuticals Gmbh Pigmentepithelzelle des Auges, ihre Herstellung und Verwendung in der Therapie einer Augen- oder Nervenerkrankung
WO2002092756A2 (en) 2001-05-15 2002-11-21 Rappaport Family Institute For Research In The Medical Sciences Insulin producing cells derived from human embryonic stem cells
CA2453438C (en) 2001-07-12 2016-04-05 Geron Corporation Cells of the cardiomyocyte lineage produced from human pluripotent stem cells
CA2468292A1 (en) * 2001-11-26 2003-06-05 Advanced Cell Technology, Inc. Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells
ATE526041T1 (de) 2001-12-11 2011-10-15 Fibrogen Inc Verfahren zur hemmung okularer vorgänge
MXPA04010282A (es) 2002-04-18 2005-08-18 Acuity Pharmaceuticals Inc Medios y metodos para la inhibicion especifica de genes en celulas y tejido de cns y/u ojo.
US7422736B2 (en) 2002-07-26 2008-09-09 Food Industry Research And Development Institute Somatic pluripotent cells
CN1720055A (zh) * 2002-10-04 2006-01-11 组织技术公司 视网膜上皮细胞在羊膜上的培养和移植
JP4348706B2 (ja) * 2002-10-08 2009-10-21 日本電気株式会社 アレイ装置および携帯端末
AU2003302020B2 (en) * 2002-11-14 2008-01-31 Ethicon Endo-Surgery, Inc. Methods and devices for detecting tissue cells
JP2007501407A (ja) * 2003-03-03 2007-01-25 長岡実業株式会社 多様な細胞タイプの検出および定量に使用される方法および装置並びにこれを行うための光バイオディスクの使用
US7794704B2 (en) * 2004-01-23 2010-09-14 Advanced Cell Technology, Inc. Methods for producing enriched populations of human retinal pigment epithelium cells for treatment of retinal degeneration
SG10201606441SA (en) 2004-01-23 2016-09-29 Astellas Inst For Regenerative Medicine Improved modalities for the treatment of degenerative diseases of the retina
CA3015835A1 (en) 2004-11-04 2006-05-18 Astellas Institute For Regenerative Medicine Derivation of embryonic stem cells
DE602006016735D1 (de) 2005-02-11 2010-10-21 Agency Science Tech & Res Verfahren zur proliferation von stammzellen
KR100832592B1 (ko) 2006-08-17 2008-05-27 박현숙 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법
JP5395058B2 (ja) 2007-04-18 2014-01-22 ハダシット メディカル リサーチ サーヴィシーズ アンド ディヴェロップメント リミテッド 幹細胞に由来する網膜色素上皮細胞
JP2008307007A (ja) * 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
AU2008312007A1 (en) 2007-10-12 2009-04-23 Advanced Cell Technology, Inc. Improved methods of producing RPE cells and compositions of RPE cells
HU0700675D0 (en) 2007-10-15 2007-12-28 Mta Tamogatott Kutatohelyek Ir Method for monitoring stem cell differentiation
US20090233324A1 (en) * 2008-03-11 2009-09-17 Kopf-Sill Anne R Methods for Diagnosing Cancer Using Samples Collected From A Central Vein Location or an Arterial Location
US8652123B2 (en) * 2008-09-02 2014-02-18 Geoffrey C. GURTNER Methods and devices for improving the appearance of tissue
US10485829B2 (en) 2009-11-17 2019-11-26 Astellas Institute For Regenerative Medicine Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells
CA2806127C (en) 2010-07-23 2021-12-21 Advanced Cell Technology, Inc. Methods for detection of rare subpopulations of cells and highly purified compositions of cells
WO2012149484A2 (en) 2011-04-29 2012-11-01 University Of Southern California Method of cryopreservation of stem cell-derived retinal pigment epithelial cells on polymeric substrate
DK2780022T3 (da) 2011-11-14 2019-07-15 Astellas Inst For Regenerative Medicine Farmaceutiske præparater af humane rpe-celler og anvendelser deraf
US9850463B2 (en) 2012-02-01 2017-12-26 The Regents Of The University Of California Methods of culturing retinal pigmented epithelium cells, including xeno-free production, RPE enrichment, and cryopreservation
EP2882846B1 (en) 2012-06-05 2018-09-05 The Regents of the University of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells

Also Published As

Publication number Publication date
US7736896B2 (en) 2010-06-15
HK1207821A1 (en) 2016-02-12
MX2020009456A (es) 2020-10-12
JP2018086274A (ja) 2018-06-07
EP4248752A2 (en) 2023-09-27
US20070031386A1 (en) 2007-02-08
AU2010249263A1 (en) 2011-01-06
AU2013201791A1 (en) 2013-04-11
AU2013201791B2 (en) 2016-08-18
CA2937099A1 (en) 2005-08-04
IL291162A (en) 2022-05-01
EP2929782A1 (en) 2015-10-14
AU2005207042B2 (en) 2010-09-09
CA2555370A1 (en) 2005-08-04
JP2024038460A (ja) 2024-03-19
JP2012148085A (ja) 2012-08-09
EP1708575A4 (en) 2009-07-01
SG10201912182UA (en) 2020-02-27
AU2005207042A1 (en) 2005-08-04
WO2005070011A2 (en) 2005-08-04
JP2019217356A (ja) 2019-12-26
JP2020146575A (ja) 2020-09-17
CN1968608B (zh) 2011-06-29
US9649340B2 (en) 2017-05-16
WO2005070011A3 (en) 2005-10-13
EP2438815A2 (en) 2012-04-11
CN104434979A (zh) 2015-03-25
JP2016195862A (ja) 2016-11-24
AU2016259323B2 (en) 2019-01-31
EP2438816A2 (en) 2012-04-11
US20100299765A1 (en) 2010-11-25
US7795025B2 (en) 2010-09-14
US9040770B2 (en) 2015-05-26
AU2021200601A1 (en) 2021-03-04
EP1708575A2 (en) 2006-10-11
HK1216068A1 (zh) 2016-10-14
CN102204930A (zh) 2011-10-05
AU2019200513A1 (en) 2019-02-14
EP4248751A2 (en) 2023-09-27
CN1968608A (zh) 2007-05-23
US20180064761A1 (en) 2018-03-08
US9730962B2 (en) 2017-08-15
EP2438816B1 (en) 2019-03-27
HK1162931A1 (en) 2012-09-07
EP4269561A3 (en) 2024-01-03
CN102204930B (zh) 2014-12-03
EP2438814A3 (en) 2012-10-03
EP4248751A3 (en) 2023-11-01
MX343606B (es) 2016-11-11
KR20130025953A (ko) 2013-03-12
BRPI0507074A (pt) 2007-06-19
IL177015B (en) 2019-06-30
SG188122A1 (en) 2013-03-28
EP2438815A3 (en) 2012-10-03
IL267126B (en) 2022-04-01
NZ548929A (en) 2010-10-29
JP2007522131A (ja) 2007-08-09
SG10201606441SA (en) 2016-09-29
JP2015096556A (ja) 2015-05-21
KR20070069087A (ko) 2007-07-02
EP4248752A3 (en) 2024-01-03
EP2438814A2 (en) 2012-04-11
EP2438816A3 (en) 2012-10-03
US20150328261A1 (en) 2015-11-19
SG155236A1 (en) 2009-09-30
US20110117062A1 (en) 2011-05-19
US20060018886A1 (en) 2006-01-26
KR20120051754A (ko) 2012-05-22
IL267126A (en) 2019-08-29
KR101258292B1 (ko) 2013-04-25
CA2555370C (en) 2024-02-06
AU2010249263B2 (en) 2013-04-18
JP2022153630A (ja) 2022-10-12
AU2016259323A1 (en) 2016-12-01
IL177015A0 (en) 2006-12-10
JP2014079650A (ja) 2014-05-08
KR101398356B1 (ko) 2014-05-23
EP4269561A2 (en) 2023-11-01

Similar Documents

Publication Publication Date Title
ES2721174T3 (es) Modalidades mejoradas para el tratamiento de enfermedades degenerativas de la retina
ES2527444T3 (es) Células del epitelio pigmentario de la retina derivadas de células madre
GB2564582A (en) Systems and methods for growth of intestinal cells in microfluidic devices
CL2020002805A1 (es) Método para identificar un modulador de un sistema biológico; método para identificar un modulador de un proceso de enfermedad (divisional 201302526)
CO2020012583A2 (es) Métodos para tratar las enfermedades asociadas al vph
GB2434157A (en) Platelets from stem cells
WO2007100692A3 (en) Method of generating human retinal progenitors from embryonic stem cells
NZ609731A (en) Compositions of adult organ stem cells and uses thereof
AR080434A1 (es) Metodo para purificar celulas derivadas de celulas madre pluripotenciales
NZ596162A (en) Pharmaceutical composition for the treatment of heart diseases
BR112014010776A8 (pt) neurônios dopaminérgicos (da) mesencefálicos para enxerto
SE1550189A1 (en) Therapeutic and prophylactic composition produced by microbiota
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
AU2005221582A8 (en) Tissue repair with multipotent cells
WO2012174338A3 (en) Method of selecting therapeutic indications
GB0704640D0 (en) Isolation of stem/progenitor cells from amniotic membrane of umbilical cord
EP1731177A4 (en) BIOLOGICAL TISSUE SHEET, METHOD OF FORMATION THEREOF AND TRANSPLANTATION METHOD USING THE SHEET
AR060841A1 (es) Produccion de etanol en hospedantes no recombinantes
MX2009006469A (es) Metodo de duplicacion del virus de la influenza en cultivo.
AR046123A1 (es) Aislamiento de celulas simil-celulas madre, uso de las mismas
WO2012112737A3 (en) Alzheimer's disease cellular model for diagnostic and therapeutic development
Sanie-Jahromi et al. Enhanced generation of retinal progenitor cells from human retinal pigment epithelial cells induced by amniotic fluid
WO2007136760A3 (en) Method of growth of mesenchymal cells under non-adherent conditions for clinical applications
MX2010005863A (es) Proceso para reducir los efectos de la enfermedad injerto contra receptor con el uso de celulas t reguladoras cd4+cd25+ expandidas ex vivo.